P-224: Pomalidomide, bortezomib, and dexamethasone after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): A safety subanalysis of the phase 3 OPTIMISMM trial — Katja Weisel (2021) | RDL Network
P-224: Pomalidomide, bortezomib, and dexamethasone after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): A safety subanalysis of the phase 3 OPTIMISMM trial
Meletios A Dimopoulos, Katja Weisel, Philippe Moreau, Larry D. Anderson, Darrell White, Jesús F. San Miguel, Pieter Sonneveld, Monika Engelhardt, Matthew Jenner, Alessandro Corso, Jan Dürig, Michel Pavic, Morten Salomo, Eva Casalz, Ruiyun Jiang, Shankar Srinivasan, Tuong Vi Nguyen, Amine Bensmaine, Teresa Peluso, Paul G. Richardson
Meletios A Dimopoulos, Katja Weisel, Philippe Moreau, Li JR, Darrell White, J.S. Miguel, Pieter Sonneveld, Monika Engelhardt, Matthew Jenner, Alessandro Corso, J. Dürig, Michel Pavic, Morten Salomo, Eva Casal, Ruixuan Jiang, Thao Thi Thu Nguyen, Teresa Peluso, Paul G. Richardson
Meletios A Dimopoulos, Katja Weisel, Philippe Moreau, Larry Anderson, Darrell White, Jesús F. San Miguel, Pieter Sonneveld, Monika Engelhardt, Matthew Jenner, Alessandro Corso, J. Dürig, Michel Pavic, Morten Salomo, Xiaoyong Yu, Tuong Vi Nguyen, Amine Bensmaine, Teresa Peluso, Mounir Zaki, Paul G. Richardson
Paul G. Richardson, Albert Oriol, Meral Beksaç, Anna Marina Liberati, Mónica Galli, Fredrik Schjesvold, Jindriska Lindsay, Katja Weisel, Darrell White, Thierry Façon, Jesús F. San Miguel, Kazutaka Sunami, Peter O’Gorman, Pieter Sonneveld, Paweł Robak, С. В. Семочкин, Steve Schey, Xin Yu, Thomas Doerr, Amine Bensmaine, Tsvetan Biyukov, Teresa Peluso,
Discussion(0)
No comments yet. Be the first to comment.